A5 Labs has completed the acquisition of the Contract Research (CRO) and Interferon production technology announced on May 7, 2010. The company plans to immediately secure the intellectual property related to the interferon production technology as well as complete its plans for pilot scale production and commercialization of interferon products for veterinary and human applications.
In addition, with the acquisition of the CRO assets, the company has established the capacity for contract analytical, product development, regulatory and testing services in the pharmaceutical and environmental sector.
“We are very pleased to complete the acquisition of the CRO and Interferon production technology assets. We now have at our disposal the necessary assets to develop and commercialize novel biotechnology products,” said Dr. Richard Azani, President and CEO.
